Figure 2.
CBDRP expression in atypical parkinsonian syndromes. Left: CBDRP expression in 10 patients with CBD (CBDNS), 30 patients with PSP (PSPNS) and 40 patients with MSA (MSANS) scanned with FDG PET at the North Shore University Hospital. The patients in the CBDNS group showed higher CBDRP expression than both the PSPNS (P < 0.05; Mann-Whitney test) and MSANS (P < 0.001) patient groups. Right: CBDRP expression in independent groups of seven CBD (CBDFR), 21 PSP (PSPFR) and 12 MSA (MSAFR) patients scanned with FDG PET at the University of Freiburg. In these groups, CBDRP expression was significantly elevated in the patients with CBD compared with the patients with MSA (P < 0.001; Mann-Whitney test), but was not different from the patients with PSP (P = 0.96). In addition, both PSPNS and PSPFR patients showed higher CBDRP expression (P < 0.001; Mann-Whitney test) than the normal (NLNS) control subjects. Error bars represent SE. **P ≤ 0.001, Mann-Whitney tests, compared to normal control subjects.